Analysed JYONG BIOTECH LTD (MENS:NASDAQ) News Sources
Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2
28-03-2026
yahoo.com
Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia
13-02-2026
yahoo.com
CEO Fu-Feng Kuo, Jyong Biotech Ltd.'s (NASDAQ:MENS) largest shareholder sees value of holdings go down 23% after recent drop
10-02-2026
yahoo.com
Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value
30-01-2026
yahoo.com
Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS‑2 Market Entry
04-12-2025
yahoo.com
Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs
24-11-2025
yahoo.com
Exploring Jyong Biotech’s (NasdaqGM:MENS) Valuation Following Recent Share Price Volatility
21-11-2025
yahoo.com
What is the current price of JYONG BIOTECH LTD (MENS:NASDAQ)?
The current price of JYONG BIOTECH LTD (MENS:NASDAQ) is $2.49.
JYONG BIOTECH LTD (MENS:NASDAQ) absolute price change since previous trading day?
The absolute price change of JYONG BIOTECH LTD (MENS:NASDAQ) since the previous trading day is $-0.19.
JYONG BIOTECH LTD (MENS:NASDAQ) percentage price change since previous trading day?
The percentage price change of JYONG BIOTECH LTD (MENS:NASDAQ) since the previous trading day is -7.0896%.
What is the most recent average sentiment score for JYONG BIOTECH LTD (MENS:NASDAQ)?
The most recent average sentiment score for JYONG BIOTECH LTD (MENS:NASDAQ) is 72 out of 100.
What is the most recent average sentiment for JYONG BIOTECH LTD (MENS:NASDAQ)?
The most recent sentiment for JYONG BIOTECH LTD (MENS:NASDAQ) is .
SEC-8K** Filing Available For JYONG BIOTECH LTD (MENS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.